Image 1 of 2
Image 2 of 2
Embrace Targeted Fat Loss with AOD9604
AOD9604, a synthetic hexadecapeptide fragment (amino acids 177-191) derived from the C-terminal lipolytic domain of human growth hormone (hGH), is engineered to mimic the fat-burning effects of hGH without influencing growth, IGF-1 levels, or insulin sensitivity. Administered via subcutaneous injection, it selectively stimulates lipolysis (fat breakdown) while inhibiting lipogenesis (new fat formation), making it a focused tool for body composition optimization. Originally developed as an obesity therapeutic, AOD9604's non-hormonal profile ensures broad tolerability, with 2025 analyses reaffirming its safety from legacy trials—though large-scale modern studies remain limited, positioning it as a promising adjunct to diet and exercise in wellness protocols.
Targeted Fat Reduction and Weight Management: Promotes up to 1.8 kg greater weight loss over 12 weeks compared to placebo in obese adults, with enhanced breakdown of abdominal and visceral fat via beta-3 adrenergic receptor upregulation—ideal for stubborn areas without overall muscle loss.
Boosted Lipid Metabolism: Accelerates fat oxidation and energy expenditure, improving overall metabolic efficiency in obese models and humans—potentially aiding those with metabolic syndrome.
Improved Cholesterol and Cardiovascular Markers: Demonstrates favorable shifts in lipid profiles, reducing total cholesterol and triglycerides in Phase 2 trials, supporting heart health alongside fat loss without glucose disruptions.
Exceptional Safety and Minimal Side Effects: Well-tolerated across six clinical trials involving ~900 participants, with no serious adverse events, anti-drug antibodies, or HGH-related risks like joint pain or insulin resistance—even at chronic doses up to 1 mg daily.
Bone Health and Recovery Support: Shows potential in preclinical models for mitigating postmenopausal bone loss, enhancing density without growth promotion—beneficial for aging populations seeking metabolic and skeletal vitality.
Drawing from foundational trials (2001-2007) and 2025 expert reviews, AOD9604 offers a low-risk entry into peptide-based fat management, though efficacy may vary without lifestyle integration.
Wellness Store Disclaimer: We don't sell or prescribe medications. Instead, we connect you to licensed professionals who can guide your journey responsibly.
Because we are not the medical provider, there is a $20 clinical consult fee that is handled directly by the medical group during your intake—similar to a telehealth visit. Once the clinician approves your case and issues your prescription, that $20 fee runs automatically. This fee is separate from your Destination Regen Wellness Store Order. However, a $20 credit will automatically be applied in your cart to offset this required fee.
